On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% yr over yr, beating the consensus of $2.01.
The pharmaceutical large reported gross sales of $22.52 billion, up 5.3% yr over yr and beating the consensus of $22.44 billion.
Operational development was 6.7%, and adjusted operational development was 5.7%.
Raymond James famous that the corporate’s preliminary 2025 EPS steerage was barely higher than anticipated, regardless of dealing with overseas alternate (FX) challenges. Nevertheless, the MedTech section stays weak, with Johnson & Johnson defending its place in key franchises.
Additionally Learn: FDA Approves Johnson & Johnson’s Remedy As First Monotherapy For Remedy-Resistant Melancholy
Raymond James analyst Jayson Bedford wrote that elevated M&A exercise may help long-term development, however near-term challenges embody delicate electrophysiology (EP) efficiency and the impression of Stelara’s lack of exclusivity. The analyst maintained an Outperform ranking.
BofA Securities considered Johnson & Johnson as pretty valued, noting its above-average price-to-earnings (P/E) ratio however solely common long-term development prospects based mostly on their evaluation.
Potential upside may rely upon the end result of talc litigation anticipated within the first half of the yr, and outcomes from late-stage scientific trials for Johnson & Johnson’s pipeline medicine.
BofA analyst Tim Anderson barely lowered the value forecast from $160 to $159 with a Impartial ranking.
Stifel famous Johnson & Johnson began the fourth-quarter 2024 MedTech earnings season on a usually optimistic notice. Nevertheless, the MedTech division confronted challenges from elevated competitors in PFA catheter adoption and China’s volume-based procurement (VBP) insurance policies. Whereas these pressures are anticipated to persist, the division’s general outlook stays optimistic.
MedTech development was anticipated to select up within the second half of 2025 because the enterprise strikes previous more durable year-over-year comparisons within the first quarter and advantages from momentum gained by newly launched merchandise all year long.
Stifel analyst Rick Smart maintained a Maintain ranking on Johnson & Johnson shares, and instructed there could also be higher alternatives to speculate based mostly on timing and valuation.
Goldman Sachs analyst Chris Shibutani mentioned the oncology section, as soon as once more headlined by the very robust a number of myeloma franchise, delivered but once more amid excessive expectations.
The challenges unsurprisingly percolate inside immunology, the place some turbulence for Tremfya added to the burden of accountability for the product forward of key IBD launches.
JNJ Value Motion: Johnson & Johnson inventory was up 1% at $146.80 eventually publication Thursday.
Learn Subsequent:
Picture: Shutterstock
Overview Ranking:
Speculative
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
